Monday, July 14, 2025

PCI Pharma invests in infrastructure for controlled substances packaging

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Nefab Expands with Plasticos Flome for Sustainable Solutions

Nefab Group acquires Plasticos Flome to expand its offering...

Critical Role of Thermal Packaging Solutions in Logistics

Thermal Packaging Solutions are of Great Importance in Logistics Transporting...

Medical Courier Industry: Key Trends & Future Growth 2033

At the leading edge of the healthcare revolution is...

PCI Pharma Services is making an investment in its infrastructure for controlled substances packaging to support the production capacity for blister packaging.

The company has made this decision in line with the recent calls for dispensing opioid prescriptions in limited quantity unit dose packaging to combat substance misuse.

PCI has invested in the extension of onsite controlled substance storage at its US commercial packaging locations in Philadelphia, Pennsylvania, and Rockford, Illinois.

The company has dedicated nearly two million square feet of packaging infrastructure at the two locations to support the US DEA Schedule I-V controlled substances for commercial prescription medicines and investigational clinical trials.

It also plans to undertake further expansions following an increase in the demand for specialised requirements and focus on introducing new child-resistant unit dose blister packaging in various formats.

PCI sales and marketing senior vice-president Phil DiGiacomo said: “A critical factor in that narrative is to ensure safety in the home. Opioid packaging demands the highest levels of child resistance.

“PCI is in a unique position to make this specialised packaging immediately available by virtue of our proven, highly automated, high-speed solutions, helping our pharmaceutical clients in their transition to meet the latest legislative requirements.

“These child-resistant packaging solutions protect younger people in the home and provide an adherence platform supporting the user to take medication as prescribed.”

Earlier this month, PCI announced an investment of more than $20m to expand Biotech clinical and commercial packaging as well as release testing capabilities at its centre of excellence in Philadelphia, US.

Latest stories

Related stories

Nefab Expands with Plasticos Flome for Sustainable Solutions

Nefab Group acquires Plasticos Flome to expand its offering...

Critical Role of Thermal Packaging Solutions in Logistics

Thermal Packaging Solutions are of Great Importance in Logistics Transporting...

Medical Courier Industry: Key Trends & Future Growth 2033

At the leading edge of the healthcare revolution is...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back